← Back to the page you were readingYou opened this term from another page.
IP · EnforcementTask: Check a product

Bolar exemption

Also called Bolar safe harbor, regulatory review safe harbor, 271(e)(1) safe harbor

Published by Patsnap Team First published Last updated 3 sources
Definition

Bolar exemption refers in the United States to the safe harbor in 35 U.S.C. 271(e)(1) for specified acts involving a patented invention, subject to statutory limits, solely for uses reasonably related to developing and submitting information under qualifying federal law1.

Governed byIn the United States, 35 U.S.C. 271(e)(1)1
AppliesTo qualifying preclinical uses of patented compounds under the US Supreme Court's 2005 Merck decision2
Comes upIn regulatory work for drugs, including research for an Abbreviated New Drug Application where the applicable US conditions are met1,2
Also seeEU Directive 2001/83/EC, Article 10(6), for certain studies, trials, and related acts3
01

What the US statute covers

Section 271(e)(1) makes it noninfringing to make, use, offer to sell, or sell a patented invention within the United States, or to import it into the United States, solely for uses reasonably related to developing and submitting information under a federal law regulating the manufacture, use, or sale of drugs or veterinary biological products, subject to the statute's exclusion1.

The exclusion applies to a new animal drug or veterinary biological product, as those terms are used in the Federal Food, Drug, and Cosmetic Act and the Act of March 4, 1913, if the product is manufactured primarily using recombinant DNA, recombinant RNA, hybridoma technology, or another process involving site-specific genetic manipulation techniques1.

02

How Merck applied the reasonable-relation requirement

In Merck KGaA v. Integra Lifesciences I (2005), the US Supreme Court said a use is reasonably related at least when a drugmaker has a reasonable basis for believing that a patented compound may produce a particular physiological effect through a particular biological process and uses it in research that, if successful, would be appropriate for inclusion in an FDA submission2.

The US Supreme Court in Merck (2005) also held that leaving the experiment's data out of an FDA submission does not, by itself, make use of the compound in that experiment infringing2.

03

The separate EU provision for human medicines

ProvisionScope and legal effect
United States: section 271(e)(1)The specified acts are not infringement if they are solely for qualifying uses under the federal-law test and the statutory exclusion does not apply1.
European Union: Directive 2001/83/EC, Article 10(6)For medicinal products, Article 10(6) treats the necessary studies and trials for the purpose of applying Article 10(1) through (4) and the consequential practical requirements as activities that do not conflict with patent rights or supplementary protection certificates3.
04

Questions people ask

Patsnap EurekaEureka IP

Check a product

FTO Search AI Agent

Turn product details into a reviewable search strategy, focused patent candidates, and evidence your IP team can take further.

Run FTO Search
Is the US safe harbor limited to generic drug research?

No, the US Supreme Court in Merck (2005) held that section 271(e)(1) is not confined to research relevant to filing an abbreviated application for generic drug approval; the statutory reasonable-relation requirement and other limits still apply1,2.

Can US preclinical studies qualify?

Yes, the US Supreme Court in Merck (2005) said that use of patented compounds in preclinical studies can qualify when there is a reasonable basis to believe the experiments will produce the types of information relevant to an investigational new drug application or a new drug application, subject to the statutory limits1,2.

Does the EU provision address supplementary protection certificates as well as patents?

Yes. Article 10(6) covers both patent rights and supplementary protection certificates for medicinal products with respect to the necessary studies and trials for the purpose of applying Article 10(1) through (4) and the consequential practical requirements3.

05

How it connects

Next step

Go from the term to the task

Read how the method works, run it on your own product or idea, then try a free tool.

  • 01 / How-toHow to run a freedom-to-operate analysisScope, search, claim review and the report counsel will ask for.GuideRead
  • 02 / AI agentFTO Search AI AgentTurn product details into a reviewable search strategy, focused patent candidates, and evidence your IP team can take further.Patsnap EurekaRun it
PublishedPatsnap Team
First published 19 November 2026
Last updated 19 November 2026
Sources
  1. 35 U.S.C. 271: Infringement of patent. United States Congress · statute · 2010. Accessed 19 November 2026.
  2. Merck KGaA v. Integra Lifesciences I, Ltd., 545 U.S. 193 (2005). Supreme Court of the United States · opinion · 2005. Accessed 19 November 2026.
  3. Directive 2001/83/EC on the Community code relating to medicinal products for human use (consolidated 1 January 2025). European Parliament and Council of the European Union · directive · 2001. Accessed 19 November 2026.
Disclaimer

General information only. This page explains a term and is provided for general information and reference only. It is not legal advice and must not be relied upon as such. It does not create an attorney-client relationship.

Sources and accuracy. Statements on this page are intended to be either general background or linked to a source listed under Sources. The explanations summarize and simplify those sources and leave out detail. Where this page differs from a cited source or from the current official text of a law or standard, rely on that source or text.

Rules vary and change. The law, standards and practice described here differ between jurisdictions and change through legislation, court decisions and revisions to official guidance and standards. This page was last checked against its sources on 19 November 2026 and may not reflect later changes. Check the current rules and official guidance in each jurisdiction that applies to you.

No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.

No characterisation of the parties or the outcome. Where this page cites a court record or decision, it reports what that record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed. The filing of a claim is not a court finding, and a docket marked “closed” does not by itself establish infringement, validity, settlement or a decision on the merits.

Third-party names and marks. Party, attorney, judge and company names appear for identification only. Company names may be trademarks of their owners; their appearance does not, by itself, imply affiliation with or endorsement by Patsnap.

Corrections. If you believe a statement on this page is inaccurate or out of date, use “Share feedback” at the bottom of this page and tell us which statement and why.

FTO Search AI AgentRun FTO Search in Patsnap EurekaStart →

Help us improve

Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.